Cargando…

Suppression of RhoG activity is mediated by a syndecan 4–synectin–RhoGDI1 complex and is reversed by PKCα in a Rac1 activation pathway

Fibroblast growth factor 2 (FGF2) is a major regulator of developmental, pathological, and therapeutic angiogenesis. Its activity is partially mediated by binding to syndecan 4 (S4), a proteoglycan receptor. Angiogenesis requires polarized activation of the small guanosine triphosphatase Rac1, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Elfenbein, Arye, Rhodes, John M., Meller, Julia, Schwartz, Martin A., Matsuda, Michiyuki, Simons, Michael
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712988/
https://www.ncbi.nlm.nih.gov/pubmed/19581409
http://dx.doi.org/10.1083/jcb.200810179
_version_ 1782169545778135040
author Elfenbein, Arye
Rhodes, John M.
Meller, Julia
Schwartz, Martin A.
Matsuda, Michiyuki
Simons, Michael
author_facet Elfenbein, Arye
Rhodes, John M.
Meller, Julia
Schwartz, Martin A.
Matsuda, Michiyuki
Simons, Michael
author_sort Elfenbein, Arye
collection PubMed
description Fibroblast growth factor 2 (FGF2) is a major regulator of developmental, pathological, and therapeutic angiogenesis. Its activity is partially mediated by binding to syndecan 4 (S4), a proteoglycan receptor. Angiogenesis requires polarized activation of the small guanosine triphosphatase Rac1, which involves localized dissociation from RhoGDI1 and association with the plasma membrane. Previous work has shown that genetic deletion of S4 or its adapter, synectin, leads to depolarized Rac activation, decreased endothelial migration, and other physiological defects. In this study, we show that Rac1 activation downstream of S4 is mediated by the RhoG activation pathway. RhoG is maintained in an inactive state by RhoGDI1, which is found in a ternary complex with synectin and S4. Binding of S4 to synectin increases the latter's binding to RhoGDI1, which in turn enhances RhoGDI1's affinity for RhoG. S4 clustering activates PKCα, which phosphorylates RhoGDI1 at Ser(96). This phosphorylation triggers release of RhoG, leading to polarized activation of Rac1. Thus, FGF2-induced Rac1 activation depends on the suppression of RhoG by a previously uncharacterized ternary S4–synectin–RhoGDI1 protein complex and activation via PKCα.
format Text
id pubmed-2712988
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-27129882010-01-13 Suppression of RhoG activity is mediated by a syndecan 4–synectin–RhoGDI1 complex and is reversed by PKCα in a Rac1 activation pathway Elfenbein, Arye Rhodes, John M. Meller, Julia Schwartz, Martin A. Matsuda, Michiyuki Simons, Michael J Cell Biol Research Articles Fibroblast growth factor 2 (FGF2) is a major regulator of developmental, pathological, and therapeutic angiogenesis. Its activity is partially mediated by binding to syndecan 4 (S4), a proteoglycan receptor. Angiogenesis requires polarized activation of the small guanosine triphosphatase Rac1, which involves localized dissociation from RhoGDI1 and association with the plasma membrane. Previous work has shown that genetic deletion of S4 or its adapter, synectin, leads to depolarized Rac activation, decreased endothelial migration, and other physiological defects. In this study, we show that Rac1 activation downstream of S4 is mediated by the RhoG activation pathway. RhoG is maintained in an inactive state by RhoGDI1, which is found in a ternary complex with synectin and S4. Binding of S4 to synectin increases the latter's binding to RhoGDI1, which in turn enhances RhoGDI1's affinity for RhoG. S4 clustering activates PKCα, which phosphorylates RhoGDI1 at Ser(96). This phosphorylation triggers release of RhoG, leading to polarized activation of Rac1. Thus, FGF2-induced Rac1 activation depends on the suppression of RhoG by a previously uncharacterized ternary S4–synectin–RhoGDI1 protein complex and activation via PKCα. The Rockefeller University Press 2009-07-13 /pmc/articles/PMC2712988/ /pubmed/19581409 http://dx.doi.org/10.1083/jcb.200810179 Text en © 2009 Elfenbein et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jcb.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Research Articles
Elfenbein, Arye
Rhodes, John M.
Meller, Julia
Schwartz, Martin A.
Matsuda, Michiyuki
Simons, Michael
Suppression of RhoG activity is mediated by a syndecan 4–synectin–RhoGDI1 complex and is reversed by PKCα in a Rac1 activation pathway
title Suppression of RhoG activity is mediated by a syndecan 4–synectin–RhoGDI1 complex and is reversed by PKCα in a Rac1 activation pathway
title_full Suppression of RhoG activity is mediated by a syndecan 4–synectin–RhoGDI1 complex and is reversed by PKCα in a Rac1 activation pathway
title_fullStr Suppression of RhoG activity is mediated by a syndecan 4–synectin–RhoGDI1 complex and is reversed by PKCα in a Rac1 activation pathway
title_full_unstemmed Suppression of RhoG activity is mediated by a syndecan 4–synectin–RhoGDI1 complex and is reversed by PKCα in a Rac1 activation pathway
title_short Suppression of RhoG activity is mediated by a syndecan 4–synectin–RhoGDI1 complex and is reversed by PKCα in a Rac1 activation pathway
title_sort suppression of rhog activity is mediated by a syndecan 4–synectin–rhogdi1 complex and is reversed by pkcα in a rac1 activation pathway
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712988/
https://www.ncbi.nlm.nih.gov/pubmed/19581409
http://dx.doi.org/10.1083/jcb.200810179
work_keys_str_mv AT elfenbeinarye suppressionofrhogactivityismediatedbyasyndecan4synectinrhogdi1complexandisreversedbypkcainarac1activationpathway
AT rhodesjohnm suppressionofrhogactivityismediatedbyasyndecan4synectinrhogdi1complexandisreversedbypkcainarac1activationpathway
AT mellerjulia suppressionofrhogactivityismediatedbyasyndecan4synectinrhogdi1complexandisreversedbypkcainarac1activationpathway
AT schwartzmartina suppressionofrhogactivityismediatedbyasyndecan4synectinrhogdi1complexandisreversedbypkcainarac1activationpathway
AT matsudamichiyuki suppressionofrhogactivityismediatedbyasyndecan4synectinrhogdi1complexandisreversedbypkcainarac1activationpathway
AT simonsmichael suppressionofrhogactivityismediatedbyasyndecan4synectinrhogdi1complexandisreversedbypkcainarac1activationpathway